Family · Pharmaceutical analytical standards
Lifitegrast
Eye drops for dry eye disease, approved in the United States in 2016: it mimics the docking site of the ICAM-1 protein and blocks the LFA-1 receptor on T lymphocytes, calming inflammation on the eye's surface. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?Many patients notice an unusual taste in the mouth after the drops: the solution probably drains through the tear ducts, which connect the eye to the nose and throat.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
